198results about How to "Reduce bleeding risk" patented technology

A bipolar surgical device includes a pair of actuable jaws. A first electrode member which optionally includes a line of electrically coupled tissue-penetrating elements is formed on one of the jaws, and a second electrode member which optionally includes a line of electrically coupled tissue-penetrating elements is formed on the same or the other jaw. The electrode members are laterally spaced-apart and arranged in a parallel, usually linear manner so that the lateral distance therebetween remains generally constant. In operation, tissue may be grasped between the jaws so that the electrode members contact and/or the tissue-penetrating elements enter into the tissue. By energizing the electrode members at opposite polarities using a high frequency energy source, tissue between the jaws will be heated, coagulated, and/or necrosed, while heating of tissue outside of the lines will be minimized.

The invention relates to the field of blood coagulation. Novel oxazolidinone derivatives of the general formula (I)

processes for their preparation and their use as medicinally active compounds for the prophylaxis and/or treatment of disorders are described.

Systems and methods for removal of thrombus from a blood vessel in a body of a patient are disclosed herein. The method can include: providing a thrombus extraction device including a proximal self-expanding member formed of a unitary fenestrated structure, a distal substantially cylindrical portion formed of a net-like filament mesh structure, and an inner shaft member connected to a distal end of the net-like filament mesh structure; advancing a catheter constraining the thrombus extraction device through a vascular thrombus, deploying the thrombus extraction; retracting the thrombus extraction device to separate a portion of the thrombus from the vessel wall and to capture the portion of the thrombus within the net-like filament mesh structure; and withdrawing the thrombus extraction device from the body to remove thrombus from the patient.

Systems and methods for removal of thrombus from a blood vessel in a body of a patient are disclosed herein. The method can include: providing a thrombus extraction device including a proximal self-expanding member formed of a fenestrated structure, a substantially cylindrical portion formed of a net-like filament mesh structure having a proximal end coupled to a distal end of the fenestrated structure; advancing a catheter constraining the thrombus extraction device through a vascular thrombus, deploying the thrombus extraction device by stacking a portion of the net-like filament mesh structure outside of the catheter by distally advancing the self-expanding member until the self-expanding member is beyond a distal end of the catheter; retracting the self-expanding member to unstack the portion of the net-like filament mesh structure and to capture the portion of the thrombus; and withdrawing the thrombus extraction device from the body.

The present invention comprises ligands and methods of manufacture thereof as well as pharmaceutical preparations including the ligands. The ligands may be human or humanized monoclonal antibodies and fragments, derivatives and homologs thereof. These may exhibit an unforeseen “plateau effect”, i.e. the achievement of only a partial inactivation of a factor involved in hemostasis, in particular in the coagulation cascade, either individually or in combination even in molar excess. The ligands may bind to a factor or a complex of factors resulting in only partially impairing the function of a physiologically functional site of the said factor or factor complex even in molar excess. This makes the ligands particularly suitable for treating coagulation disorders and resulting thrombotic pathologic conditions while minimizing the risk of bleeding. Particularly useful is a property of ligands in accordance with the present invention to allow some physiological function of the affected site even when the ligand is in molar excess. The ligands may be anti-factor VIII antibodies or antibodies against a factor VIII complex, in particular human or human hybrid monoclonal antibodies which bind to factor VIII or a factor VIII complex and at least partially inhibit the activity of factor VIII.

The present invention relates to a microwave radiation antenna capable of making percutaneous puncture to cure tumor of several regions of human body. Said invention is formed from antenna connector, hard coaxial line, ceramic tube, water inlet tube, water outlet tube, temperature-measuring system, stainless steel sleeve and handle. Its output power can be up to above 100w, and is therapeutic effect is reliable and safe.

Glycosaminoglycans derived from K5 polysaccharide having high anticoagulant and antithrombotic activity and useful for the control of coagulation and as antithrombotic agents are obtained starting from an optionally purified K5 polysaccharide by a process comprising the steps of N-deacetylation/N-sulfation, C5 epimerization, O-oversulfation, selective O-desulfation, 6-O-sulfation, N-sulfation, and optional depolymerization, in which said epimerization is performed with the use of the enzyme glucoronosyl C5 epimerase in solution or in immobilized form in the presence of divalent cations. New, particularly interesting antithrombin compounds are obtained by controlling the reaction time in the selective O-desulfation step and submitting the product obtained at the end of the final N-sulfation step to depolymerization.

A self-expanding stent is delivered to an affected site within the human body with a guide wire and hand-manipulable control apparatus. The stent is capable of full expansion along a pre-determined length of its body with the remainder of the overall length conically tapering to a fixed connection point with the guide wire with a flexible joint between the sections. A covering sheath delivers the stent to the affected area with a tip capable of penetrating a blockage or obstruction in a vessel such that the stent can be exposed to begin its expansion. Once the obstruction is opened, the stent can be recaptured or retrieved by pulling it back into the sheath, collapsing the expanded stent with the assistance of the conical portion and flexible joint, and withdrawing the stent and wire completely from the vessel. A rotating motion will cause the conical and cylindrical sections of the stent to separate at the flexible joint.

Low molecular weight glycosaminoglycans derived from K5 polysaccharide having an activity of the same order of magnitude as that of low molecular weight heparin on the coagulation parameters and a lower hemorrhagic risk are obtained starting from an optionally purified K5 polysaccharide by a process comprising the sequential steps of N-deacetylation/N-sulfation, C5-epimerization, depolymerization of the obtained epiK5-N-sulfate, O-oversulfation of the LMW-epiK5-N-sulfate, selective O-desulfation, 6-O-sulfation, N-sulfation.

The present invention discloses inhibitory antibodies against Factor VIII with modified glycosylation, either by enzymatic deglycosylation or by site directed mutagenesis. Said antibodies with modified glycosylation have equal affinity for FVIII but show different inhibiting properties. The use of one or a mixture of said antibodies allow modulation of the inhibition of factor VII to levels between 40 and 95%. The present invention further disclosed pharmaceutical compositions comprising inhibitory antibodies against Factor VIII with modified glycosylation, combinations of these antibodies and methods for treating haemostasis disorders using said antibodies and antibody mixtures.

A method and medicament for treating and preventing platelet activation or thrombosis in the presence of heparin- and platelet factor 4-complex reactive antibodies using a 2-O desulfated heparin with an average degree of sulfation of 0.6 sulfate groups per monosaccharide or greater and an average molecular weight or 2.4 kD or greater. The medicament preferably is administered intravenously, by aerosolization or orally. Preferably, the 2-O desulfated heparin medicament includes a physiologically acceptable carrier which may be selected from the group consisting of physiologically buffered saline, normal saline, and distilled water. Additionally provided is a method of synthesizing 2-O desulfated heparin.